[go: up one dir, main page]

UY31101A1 - Composición antigénica liofilizada - Google Patents

Composición antigénica liofilizada

Info

Publication number
UY31101A1
UY31101A1 UY31101A UY31101A UY31101A1 UY 31101 A1 UY31101 A1 UY 31101A1 UY 31101 A UY31101 A UY 31101A UY 31101 A UY31101 A UY 31101A UY 31101 A1 UY31101 A1 UY 31101A1
Authority
UY
Uruguay
Prior art keywords
compositions
liofilized
antigenic
composition
lyophilized
Prior art date
Application number
UY31101A
Other languages
English (en)
Inventor
Dominique Ingrid Lemoine
Francoise Mathilde Maurice Hogge
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/055037 external-priority patent/WO2007137986A2/en
Priority claimed from GB0723044A external-priority patent/GB0723044D0/en
Priority claimed from GB0723900A external-priority patent/GB0723900D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of UY31101A1 publication Critical patent/UY31101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona composiciones liofilizadas que comprenden un antígeno y un agonista del receptor del tipo Toll (TRL) 9. Tales composiciones se pueden reconstituir en composiciones inmunogénicas para uso en vacunación con un vehículo seleccionado entre el grupo de vehículos particulados constituidos por liposomas, sales minerales, emulsiones, polímeros e ISCOM. Los procedimientos de preparación de composiciones inmunogénicas a partir de composiciones liofilizadas de la invención y uso de la misma en la inmunización también se proporcionan en el presente documento.
UY31101A 2007-05-24 2008-05-22 Composición antigénica liofilizada UY31101A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2007/055037 WO2007137986A2 (en) 2006-05-26 2007-05-24 Vaccination against cancer
GB0723044A GB0723044D0 (en) 2007-11-23 2007-11-23 Lyophillised antigen composition
GB0723900A GB0723900D0 (en) 2007-12-06 2007-12-06 Lyophillised antigen composition

Publications (1)

Publication Number Publication Date
UY31101A1 true UY31101A1 (es) 2009-01-05

Family

ID=39714209

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31101A UY31101A1 (es) 2007-05-24 2008-05-22 Composición antigénica liofilizada

Country Status (23)

Country Link
US (2) US20090035360A1 (es)
EP (3) EP2476431A1 (es)
JP (1) JP5331105B2 (es)
KR (2) KR101238795B1 (es)
CN (1) CN101678091A (es)
AR (1) AR066676A1 (es)
AU (1) AU2008252911B2 (es)
BR (1) BRPI0811228A2 (es)
CA (1) CA2687632C (es)
CL (1) CL2008001491A1 (es)
CY (1) CY1113446T1 (es)
DK (1) DK2148697T3 (es)
EA (3) EA201300101A1 (es)
ES (1) ES2395333T3 (es)
HR (1) HRP20121019T1 (es)
MX (1) MX2009012381A (es)
PE (1) PE20090281A1 (es)
PL (1) PL2148697T3 (es)
PT (1) PT2148697E (es)
SI (1) SI2148697T1 (es)
TW (1) TW200911304A (es)
UY (1) UY31101A1 (es)
WO (1) WO2008142133A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100028415A1 (en) 2005-04-12 2010-02-04 Haynes Barton F Method of Inducing Neutralizing Antibodies to Human Immunodeficiency Virus
EP1951281B1 (en) 2005-10-17 2015-04-15 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
US8956627B2 (en) * 2007-04-13 2015-02-17 Duke University Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates
JP2013505201A (ja) * 2009-04-03 2013-02-14 デューク ユニバーシティー 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
UA110806C2 (uk) 2010-12-14 2016-02-25 Ґлаксосмітклайн Байолоджікалз С.А. Мікобактеріальна антигенна композиція
CA2841380A1 (en) * 2011-07-22 2013-01-31 Glaxosmithkline Biologicals S.A. Prame purification
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN105377291B (zh) 2013-01-15 2019-04-02 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
IL310015B1 (en) * 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
CA2943050A1 (en) * 2014-03-25 2015-10-01 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
CA3003483C (en) 2015-11-06 2022-09-13 Adjuvance Technologies, Inc. Triterpene saponin analogues
BE1025160B1 (fr) 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa Nouveau procédé
AU2018350887A1 (en) 2017-10-16 2020-03-05 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3824019A1 (en) 2018-07-19 2021-05-26 GlaxoSmithKline Biologicals SA Processes for preparing dried polysaccharides

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827A (en) 1848-10-03 Improved table-cutlery
US666A (en) 1838-04-02 Sfbing-bock for coagh and railroad-gab
US6054438A (en) 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
JPH02501828A (ja) 1987-01-07 1990-06-21 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド プローブ
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5666153A (en) * 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
EP1017419A4 (en) * 1997-09-25 2004-12-29 Sloan Kettering Institutefor C FUCOSYL-GM1-KLH CONJUGATE VACCINE AGAINST SMALL CELL LUNG CANCER
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
CA2331769A1 (en) 1998-06-22 1999-12-29 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes
DE69929444T2 (de) * 1998-08-10 2006-09-28 Antigenics Inc., Woburn Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CA2361009C (en) 1999-01-29 2012-10-23 Corixa Corporation Her-2/neu fusion proteins
DK1165778T3 (da) 1999-03-11 2007-02-12 Glaxosmithkline Biolog Sa Anvendelser af CASB618-polynukleotider og -polypeptider
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
SI1265915T1 (sl) 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Nove spojine
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
PL207168B1 (pl) 2001-09-20 2010-11-30 Glaxo Group Ltd Sekwencja nukleotydowa, wektor, białko, środek farmaceutyczny, urządzenie do podawania śródskórnego, zastosowanie sekwencji nukleotydowej i sposób wytwarzania nukleotydu
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
AU2003297499A1 (en) * 2002-12-23 2004-07-22 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
AU2005254027A1 (en) * 2004-06-12 2005-12-29 Pharma Pacific Pty Ltd Method of enhancing the immune response to a vaccine
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006092017A1 (en) 2005-03-02 2006-09-08 Solbec Pharmaceuticals Limited Glycoalkaloid and tlr agonist combinations and various uses thereof
AU2006259220C1 (en) * 2005-06-17 2013-05-16 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma

Also Published As

Publication number Publication date
PT2148697E (pt) 2012-12-24
EP2148697B1 (en) 2012-10-03
US20090035360A1 (en) 2009-02-05
EA018201B1 (ru) 2013-06-28
EP2489367A1 (en) 2012-08-22
KR101238795B1 (ko) 2013-03-07
AR066676A1 (es) 2009-09-02
EP2476431A1 (en) 2012-07-18
TW200911304A (en) 2009-03-16
JP2010527964A (ja) 2010-08-19
US8557247B2 (en) 2013-10-15
ES2395333T3 (es) 2013-02-12
CY1113446T1 (el) 2016-06-22
MX2009012381A (es) 2009-12-01
AU2008252911A1 (en) 2008-11-27
AU2008252911B2 (en) 2013-09-05
DK2148697T3 (da) 2012-12-17
EA201300102A1 (ru) 2014-02-28
EA201300101A1 (ru) 2014-02-28
CL2008001491A1 (es) 2008-11-28
BRPI0811228A2 (pt) 2014-10-21
CA2687632C (en) 2013-01-15
HRP20121019T1 (hr) 2013-01-31
SI2148697T1 (sl) 2013-01-31
CA2687632A1 (en) 2008-11-27
KR20110091817A (ko) 2011-08-12
EA200901434A1 (ru) 2010-06-30
JP5331105B2 (ja) 2013-10-30
US20110059163A1 (en) 2011-03-10
EP2148697A1 (en) 2010-02-03
KR20100017519A (ko) 2010-02-16
WO2008142133A1 (en) 2008-11-27
PE20090281A1 (es) 2009-03-28
PL2148697T3 (pl) 2013-02-28
CN101678091A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
UY31101A1 (es) Composición antigénica liofilizada
BRPI0509606A (pt) emulsões de óleo-em-água microfluidizadas e composições para vacinas
AR078085A1 (es) Peptidos tau antigenicos y usos de los mismos
DOP2013000128A (es) Uso de células t modificadas con un receptor de antígeno quimérico para tratar el cáncer
MX337456B (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores.
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
MX2021011196A (es) Receptores de antigenos quimericos anti-antigeno de maduracion de celulas b (anti-bcma).
MX2015000433A (es) Uso de cart19 para eliminar celulas b normales para inducir tolerancia.
MX363307B (es) Plataformas para suministro de antigenos.
BR112012030552A2 (pt) composição imunogênica
MX2013001527A (es) Nuevas vacunas adyuvantes en base a adyuvantes de orientacion para anticuerpos directamente hacia celulas presentadoras de antigenos.
BRPI0715396B8 (pt) método de produção de uma composição para vacina
BR112013000394B8 (pt) Composição imunogênica, uso da mesma e método para preparar a referida composição
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
EA201100268A1 (ru) Вакцина
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
RU2009144125A (ru) Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе
MX2009007571A (es) Vacuna.
CU23759A3 (es) Composiciones inmunogénicas
BR112023019301A2 (pt) Formulações de vacina de coronavírus
WO2005000348A3 (en) Vaccines inducing nkt-cell and toll-like-receptor activation
MX2007015933A (es) Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
UY34073A (es) Vacuna mejorada de streptococcus pneumoniae y métodos de preparación.
TW200833709A (en) Archaeal polar lipid aggregates for administration to animals
TN2009000195A1 (en) Prime boost canine leishmania vaccine

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20120613